{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:11:02Z","timestamp":1791857462015,"version":"4.3.4"},"reference-count":233,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell therapy has become an important treatment for hematological cancers, and its success has spurred research into CAR T cell therapies for other diseases, including solid tumor cancers and autoimmune diseases. Notably, the development of CAR-based treatments for autoimmune diseases has shown great progress recently. Clinical trials for anti-CD19 and anti-BCMA CAR T cells in treating severe B cell-mediated autoimmune diseases, like systemic lupus erythematosus (SLE), have shown lasting remission thus far. CAR T cells targeting autoreactive T cells are beginning clinical trials for treating T cell mediated autoimmune diseases. Chimeric autoantigen receptor (CAAR) T cells specifically target and eliminate only autoreactive B cells, and they have shown promise in treating mucosal pemphigus vulgaris and MuSK myasthenia gravis. Regulatory CAR T cells have also been developed, which show potential in altering autoimmune affected areas by creating a protective barrier as well as helping decrease inflammation. These new treatments are only the beginning of potential CAR T cell applications in treating autoimmune disease. Novel CAR technologies have been developed that increase the safety, potency, specificity, and efficacy of CAR T cell therapy. Applying these novel modifications to autoimmune CARs has the potential to enhance the efficacy and applicability of CAR therapies to autoimmune disease. This review will detail several recently developed CAR technologies and discuss how their application to autoimmune disease will improve this emerging field. These include logic-gated CARs, soluble protein-secreting CARs, and modular CARs that enable CAR T cell therapies to be more specific, reach a wider span of target cells, be safer for patients, and give a more potent cytotoxic response. Applying these novel CAR technologies to the treatment of autoimmune diseases has the potential to revolutionize this growing application of CAR T cell therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1465191","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:26:48Z","timestamp":1728433608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Application of novel CAR technologies to improve treatment of autoimmune disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Abigail","family":"Cheever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe C.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Scott","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Briefings Funct Genomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1141880","article-title":"In vivo CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address","volume":"10","author":"Wakao","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724211","article-title":"Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrd.2017.196","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus Med Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/ph15020207","article-title":"Present, and future of clinically applied chimeric antigen receptor-T-cell therapy","volume":"15","author":"Fujiwara","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic Malignancies: A voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discovery"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: A roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/imj.13136","article-title":"Single-dose rituximab in refractory lupus nephritis","volume":"46","author":"Kotagiri","year":"2016","journal-title":"Intern Med J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.002","article-title":"Successful CAR T cell therapy in a heart and kidney transplant recipient with refractory PTLD","volume":"4","author":"Oren","year":"2022","journal-title":"JACC: CardioOncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001584","article-title":"CAR T-cell therapy for refractory posttransplantation lymphoproliferative disorder in a kidney transplant patient","volume":"10","author":"Guy","year":"2024","journal-title":"Transplant Direct"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.02.008","article-title":"CAR T-cell therapy\u2014paving the way for sensitized kidney transplant patients","volume":"105","author":"Jarmi","year":"2024","journal-title":"Kidney Int"},{"key":"B47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.3390\/ijms232113427","article-title":"Characterization of BCMA expression in circulating rare single cells of patients with plasma cell neoplasms","volume":"23","author":"Ndacayisaba","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymp Myeloma Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell Malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.12.5749","article-title":"Immunologic characterization of CD7-deficient mice","volume":"160","author":"Lee","year":"1998","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1170968","article-title":"Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaa006","article-title":"CAR T cells leave the comfort zone: current and future applications beyond cancer","volume":"1","author":"Mazzi","year":"2021","journal-title":"Immunother Adv"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2012.03564.x","article-title":"B-cell receptor: from resting state to activate","volume":"136","author":"Treanor","year":"2012","journal-title":"Immunology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment","volume":"11","author":"Sadeqi Nezhad","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1620602","article-title":"Regulatory T cells: the future of autoimmune disease treatment","volume":"15","author":"Ryba-Stanis\u0142awowska","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2021.11.007","article-title":"Emerging strategies for treating autoimmune disorders with genetically modified Treg cells","volume":"149","author":"Boardman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.24272\/j.issn.2095-8137.2021.363","article-title":"Engineered T cells and their therapeutic applications in autoimmune diseases","volume":"43","author":"Bao","year":"2022","journal-title":"Zool Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"104222","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715424","article-title":"The pathophysiology and treatment of graft-versus-host disease: lessons learnt from animal models","volume":"12","author":"Teshima","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","article-title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","volume":"138","author":"Henschel","year":"2023","journal-title":"J Autoimmun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.cytox.2020.100049","article-title":"Using CRISPR to enhance T cell effector function for therapeutic applications","volume":"3","author":"Freen-van Heeren","year":"2021","journal-title":"Cytokine X"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell Malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther - Nucleic Acids"},{"key":"B86","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143474","article-title":"Tandem CD19\/CD22 dual targets CAR-T cells therapy acquires superior CR rate than CD19 CAR-T cells: A case controlled study","volume":"136","author":"Cui","year":"2020","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell Malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Nobari","year":"2022","journal-title":"J Trans Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"100039","DOI":"10.1016\/j.jtauto.2020.100039","article-title":"Immune-mediated genesis of multiple sclerosis","volume":"3","author":"Cavallo","year":"2020","journal-title":"J Trans Autoimmun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1823","article-title":"Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis","volume":"8","author":"Bronge","year":"2022","journal-title":"Sci Adv"},{"key":"B95","doi-asserted-by":"publisher","first-page":"17300","DOI":"10.1038\/s41598-021-96675-z","article-title":"Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays","volume":"11","author":"Poulsen","year":"2021","journal-title":"Sci Rep"},{"key":"B96","article-title":"Autoantigens and immune pathways in rheumatoid arthritis","volume":"22","author":"Corrigall","year":"2002","journal-title":"Crit Rev Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30344-1","article-title":"Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerizing immunotherapy","volume":"2","author":"Nel","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2006.21.3.478","article-title":"Disease-specific proteins from rheumatoid arthritis patients","volume":"21","author":"Kim","year":"2006","journal-title":"J Korean Med Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187418","article-title":"And-gate CAR T-cells to improve tumor specificity and targeting of low-expression antigens in multiple myeloma","volume":"142","author":"Anderson","year":"2023","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Trans Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.11.002","article-title":"CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect","volume":"534","author":"Xia","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Trans Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41598-018-22252-6","article-title":"and SynNotch receptor for cancer therapy","volume":"8","author":"Cho","year":"2018","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signaling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.tranon.2021.101070","article-title":"Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs","volume":"14","author":"Moghanloo","year":"2021","journal-title":"Trans Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Trans Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Trans Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2326-6066.CIR-21-0095","article-title":"and dose-dependent control of TCR and CAR T-cell function","volume":"9","author":"Sahillioglu","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Trans Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1808790115","article-title":"The in silico human surfaceome","volume":"115","author":"Bausch-Fluck","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s44161-022-00200-y","article-title":"Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts","volume":"2","author":"Luecke","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1038\/s41467-021-27280-x","article-title":"Light-mediated discovery of surfaceome nanoscale organization and intercellular receptor interaction networks","volume":"12","author":"M\u00fcller","year":"2021","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0088","article-title":"Elucidating the cell surfaceome to accelerate cancer drug development","volume":"14","author":"Geri","year":"2024","journal-title":"Cancer Discovery"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2022.07.026","article-title":"CRISPR-surfaceome: An online tool for designing highly efficient sgRNAs targeting cell surface proteins","volume":"20","author":"Mei","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","article-title":"Cytokine signaling in chimeric antigen receptor T-cell therapy","volume":"36","author":"Kagoya","year":"2024","journal-title":"Int Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-gamma: A cytokine at the right time, is in the right place","volume":"43","author":"Burke","year":"2019","journal-title":"Semin Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090959","article-title":"CAR T cell therapy becomes CHIC: \u201ccytokine help intensified CAR\u201d T cells","volume":"13","author":"Thomas","year":"2022","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","article-title":"Emerging principles of cytokine pharmacology and therapeutics","volume":"22","author":"Saxton","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discovery"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610115104","article-title":"The IL-15\/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells","volume":"104","author":"Sato","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839783","article-title":"GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18","volume":"13","author":"Glienke","year":"2022","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumor stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"B143","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/BTT.S291768","article-title":"Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumor efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B145","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"B146","article-title":"Cytokines in the systemic inflammatory response syndrome: a review","volume":"2","author":"Jaffer","year":"2010","journal-title":"HSR Proc Intensive Care Cardiovasc Anesth"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.5.2444","article-title":"Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes","volume":"151","author":"Mehrotra","year":"1993","journal-title":"J Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/187152809787582507","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders","volume":"8","author":"Gee","year":"2009","journal-title":"Inflammation Allergy Drug Targets"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003208","article-title":"The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells","volume":"9","author":"Schurich","year":"2013","journal-title":"PloS Pathog"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0091-6749(99)70518-X","article-title":"IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family","volume":"103","author":"Dinarello","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.7.3400","article-title":"IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production","volume":"161","author":"Yoshimoto","year":"1998","journal-title":"J Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal","year":"2000","journal-title":"Chest"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.86.717","article-title":"Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir","volume":"86","author":"Hirano","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.3.839","article-title":"Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus","volume":"181","author":"Llorente","year":"1995","journal-title":"J Exp Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2663","article-title":"IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity","volume":"183","author":"Lee","year":"1996","journal-title":"J Exp Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/BOR.0b013e32805e87f1","article-title":"Update on cytokines in rheumatoid arthritis","volume":"19","author":"Brennan","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016791108","article-title":"Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance","volume":"108","author":"Pedicord","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B173","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","article-title":"CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies","volume":"14","author":"Liang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol Cancer"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S260915","article-title":"EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i23","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.003","article-title":"Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy","volume":"126","author":"Goleva","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.05.007","article-title":"Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy","volume":"22","author":"Zhang","year":"2020","journal-title":"Cytotherapy"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumor burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2023.01.003","article-title":"Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env(+) cells invivo","volume":"38","author":"Pan","year":"2023","journal-title":"Virol Sin"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.86632","article-title":"Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment","volume":"19","author":"Qiu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B189","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.3390\/cancers13246258","article-title":"Harnessing macrophages through the blockage of CD47: implications for acute myeloid leukemia","volume":"13","author":"Melo Garcia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","author":"Zenobia","year":"2015","journal-title":"Periodontol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cyto.2007.09.014","article-title":"IL-17\/Th17 targeting: on the road to prevent chronic destructive arthritis","volume":"41","author":"Lubberts","year":"2008","journal-title":"Cytokine"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-022-00875-5","article-title":"CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumor responses in solid cancers","volume":"6","author":"Jin","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B194","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/jcm12113801","article-title":"Immune and non-immune inflammatory cells involved in autoimmune fibrosis: new discoveries","volume":"12","author":"Sisto","year":"2023","journal-title":"J Clin Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"B197","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.3390\/ijms21197222","article-title":"Modular chimeric antigen receptor systems for universal CAR T cell retargeting","volume":"21","author":"Sutherland","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B198","doi-asserted-by":"publisher","first-page":"114358","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Advanced Drug Delivery Rev"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1834","article-title":"Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors","volume":"79","author":"Lee","year":"2019","journal-title":"Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b11622","article-title":"Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor","volume":"142","author":"Minutolo","year":"2020","journal-title":"J Am Chem Soc"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953726","article-title":"Autoantibodies - enemies, and\/or potential allies","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol"},{"key":"B205","article-title":"mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting","volume":"7","author":"Lohmueller","year":"2017","journal-title":"Oncoimmunology"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201601902","article-title":"Design of switchable chimeric antigen receptor T cells targeting breast cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"B207","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-018-0591-7","article-title":"Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B209","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5582\/bst.2018.01048","article-title":"Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer","volume":"12","author":"Chu","year":"2018","journal-title":"Biosci Trends"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00151","article-title":"Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric Malignancies","volume":"9","author":"Lu","year":"2019","journal-title":"Front Oncol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1758835920910347","DOI":"10.1177\/1758835920910347","article-title":"Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-024-01938-8","article-title":"The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B214","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"B216","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun Biol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","article-title":"Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform","volume":"179","author":"Herzig","year":"2019","journal-title":"Cell"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat Commun"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124279","article-title":"Targeting the FMS-like tyrosin kinase 3 with the unicar system: preclinical comparison of murine and humanized single-chain variable fragment-based targeting modules","volume":"134","author":"Fasslrinner","year":"2019","journal-title":"Blood"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1287246","article-title":"A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform","volume":"6","author":"Albert","year":"2017","journal-title":"Oncoimmunology"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v9i39","article-title":"From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo","volume":"9","author":"Albert","year":"2018","journal-title":"Oncotarget"},{"key":"B223","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B224","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-018-0113-4","article-title":"Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells","author":"Loureiro","year":"2018","journal-title":"Blood Cancer J"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i65","article-title":"Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells","volume":"8","author":"Mitwasi","year":"2017","journal-title":"Oncotarget"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i19","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1659095","DOI":"10.1080\/2162402X.2019.1659095","article-title":"and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR","volume":"8","author":"Arndt","year":"2019","journal-title":"Oncoimmunology"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v9i7","article-title":"Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells","volume":"9","author":"Bachmann","year":"2018","journal-title":"Oncotarget"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005054","article-title":"Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors","volume":"10","author":"Stock","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell Malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B231","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1425-7","article-title":"Modular and tunable biological feedback control using a de novo protein switch","volume":"572","author":"Ng","year":"2019","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1465191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:26:53Z","timestamp":1728433613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1465191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":233,"alternative-id":["10.3389\/fimmu.2024.1465191"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1465191","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"article-number":"1465191"}}